Opinion|Videos|May 7, 2024

Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.


Latest CME